Properties of different pancreatin preparations used in pancreatic exocrine insufficiency

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 9, 2009, Pages 1024-1031

  Löhr, Johannes Matthias ^a,d,e   Hummel, Frank M ^a   Pirilis, Konstantinos T ^b   Steinkamp, Gregor ^c   Körner, Andreas ^b   Henniges, Friederike ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Solvay Pharmaceuticals GmbH   (Germany)

^c Klinische Forschung   (Germany)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Chronic pancreatitis; Cystic fibrosis; Enzyme substitution; Pancreatic exocrine insufficiency; Pancreatin

Indexed keywords

ACID; ENZYME; KREON; PANCREATIN; PANCRELIPASE; PANGROL; PANZYTRAT; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ARTICLE; DIGESTION; DRUG EFFICACY; DUODENUM; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME RELEASE; HUMAN; PANCREAS DISEASE; PANCREAS SECRETION; PANCREAS SECRETION INSUFFICIENCY; PARTICLE SIZE; PH; PRIORITY JOURNAL; STOMACH ACID; SURFACE PROPERTY;

AMYLASES; DIGESTION; EXOCRINE PANCREATIC INSUFFICIENCY; GASTROINTESTINAL AGENTS; HUMANS; LIPASE; MICROSPHERES; PANCREATIN; PARTICLE SIZE;

EID: 69549138687     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328328f414     Document Type: Article

References (34)

1. Laass MW, Henker J, Thamm K, Neumeister V, Kuhlisch E. Exocrine pancreatic insufficiency and its consequences on physical development and metabolism in children and adolescents with type 1 diabetes mellitus. Eur J Pediatr 2004; 163:681-682. (Pubitemid 39517895)
2. Ammann RW, Akovbiantz A, Largiader F, Schueler G. Course and outcome of chronic pancreatitis. Longitudinal study of a mixed medical-surgical series of 245 patients. Gastroenterology 1984; 86 (5 Pt 1):820-828.
3. Guy-Crotte O, Carrere J, Figarella C. Exocrine pancreatic function in cystic fibrosis. Eur J Gastroenterol Hepatol 1996; 8:755-759. (Pubitemid 26275693)
4. Mossner J, Keim V, Niederau C, Buchler M, Singer MV, Lankisch PG, et al. [Guidelines for therapy of chronic pancreatitis. Consensus Conference of the German Society of Digestive and Metabolic Diseases. Halle 21-23 November 1996]. Z Gastroenterol 1998; 36:359-367.
5. Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman HG, et al. Nutrition in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2002; 1:51-75.
6. Moran CE, Sosa EG, Martinez SM, Geldern P, Messina D, Russo A, et al. Bone mineral density in patients with pancreatic insufficiency and steatorrhea. Am J Gastroenterol 1997; 92:867-871. (Pubitemid 27200808)
7. Dujsikova H, Dite P, Tomandl J, Sevcikova A, Precechtelova M. Occurrence of metabolic osteopathy in patients with chronic pancreatitis. Pancreatology 2008; 8:583-586.
8. DiMagno EP. A short, eclectic history of exocrine pancreatic insufficiency and chronic pancreatitis. Gastroenterology 1993; 104:1255-1262. (Pubitemid 23235396)
9. Layer P, Keller J. Lipase supplementation therapy: standards, alternatives, and perspectives. Pancreas 2003; 26:1-7. (Pubitemid 36020259)
10. Engesser H. Beiträge zur therapeutischen Verwendung der Bauchspeicheldrüse von Schlachtthieren und deren Präparate [in German]. Dtsch Arch Klin Med 1879; XXIV:539-582.
11. Löhr JM. Exocrine pancreatic insufficiency. 1st ed. Bremen: Uni-Med; 2007.
12. Register UFF. 60 FR 20162. In: Register F, ed; 1995.
13. Register UFF. 69 FR 23410. In: Federal Register; 2004. p. 82.
14. Puckhader M, Roethele S, Witt W. In-line laser diffraction. Proven particle size analysis in industrial environment. Powder Handling Process 1998; 10:410-421.
15. European Pharmacopeia. Disintegration of tablets and capsules. In: European Pharmacopeia, editor. European Pharmacopeia. 6.3 ed. Strasbourg: European Pharmacopeia; 2006.
16. European Pharmacopeia. Pancreas powder. In: European Pharmacopeia, editor. 0350. 6th ed. Strasbourg: European Pharmacopeia; 2008.
17. Hüwel S, Behrens R, Spenser F. Pankreasenzyme: Präparate im Vergleich [in German]. Pharmazeutische Zeitung 1996; 37:33-42.
18. Peschke GJ. Active components and galenic aspects of enzyme preparations. In: Lankisch PG, editor. Pancreatic enzymes in health and disease. Berlin: Springer Verlag; 1991. pp. 55-64.
19. Gan KH, Geus WP, Bakker W, Lamers CB, Heijerman HG. In vitro dissolution profiles of enteric-coated microsphere/microtablet pancreatin preparations at different pH values. Aliment Pharmacol Ther 1996; 10:771-775.
20. Case CL, Henniges F, Barkin JS. Enzyme content and acid stability of enteric-coated pancreatic enzyme products in vitro. Pancreas 2005; 30:180-183. (Pubitemid 40289456)
21. Aloulou A, Puccinelli D, Sarles J, Laugier R, Leblond Y, Carriere F. In vitro comparative study of three pancreatic enzyme preparations: dissolution profiles, active enzyme release and acid stability. Aliment Pharmacol Ther 2008; 27:283-292.
22. Lankisch PG, Lembcke B, Goke B, Creutzfeldt W. Therapy of pancreatogenic steatorrhoea: does acid protection of pancreatic enzymes offer any advantage? Z Gastroenterol 1986; 24:753-757.
23. Layer P, von der Ohe MR, Holst JJ, Jansen JB, Grandt D, Holtmann G, et al. Altered postprandial motility in chronic pancreatitis: role of malabsorption. Gastroenterology 1997; 112:1624-1634. (Pubitemid 27181388)
24. Keller J, Runzi M, Goebell H, Layer P. Duodenal and ileal nutrient deliveries regulate human intestinal motor and pancreatic responses to a meal. Am J Physiol 1997; 272 (3 Pt 1):G632-G637. (Pubitemid 27147366)
25. Geus WP, Eddes EH, Gielkens HA, Gan KH, Lamers CB, Masclee AA. Post-prandial intragastric and duodenal acidity are increased in patients with chronic pancreatitis. Aliment Pharmacol Ther 1999; 13:937-943.
26. Walters MP, Littlewood JM. Pancreatin preparations used in the treatment of cystic fibrosis - lipase content and in vitro release. Aliment Pharmacol Ther 1996; 10:433-440.
27. Braga M, Cristallo M, De Franchis R, Mangiagalli A, Zerbi A, Agape D, et al. Pancreatic enzyme replacement therapy in postpancreatectomy patients. Int J Pancreatol 1989; 5 (Suppl):37-44. (Pubitemid 20183023)
28. Dominguez-Munoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep 2007; 9:116-122. (Pubitemid 46647523)
29. Kraisinger M, Hochhaus G, Stecenko A, Bowser E, Hendeles L. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol 1994; 34:158-166. (Pubitemid 24079922)
30. Meyer JH, Elashoff J, Porter-Fink V, Dressman J, Amidon GL. Human postprandial gastric emptying of 1-3 millimeter spheres. Gastroenterology 1988; 94:114-119.
31. Halm U, Löser C, Löhr M, Katschinski M, Mössner J. A double-blind, randomized, multicenter, crossover study to prove equivalence of pancreatin minimicrospheres versus microspheres in exocrine pancreatic insufficiency. Aliment Pharmacol Ther 1999; 13:951-957. (Pubitemid 29312782)
32. Kühnelt P, Mundlos S, Adler G. Einfluß der Pelletgröße eines Pankreasenzympräparates auf die duodenale lipolytische Aktivität [in German]. Z Gastroenterol 1991; 29:417-421.
33. Norregaard P, Lysgaard Madsen J, Larsen S, Worning H. Gastric emptying of pancreatin granules and dietary lipids in pancreatic insufficiency. Aliment Pharmacol Ther 1996; 10:427-432. (Pubitemid 26174913)
34. Keller J, Layer P. Pancreatic enzyme supplementation therapy. Curr Treat Options Gastroenterol 2003; 6:369-374.